CS
AVTX icon

Credit Suisse’s Avalo Therapeutics AVTX Stock Holding History

Credit Suisse’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Hold
0
– – – 4037
2022
Q2 		– Hold
0
– – – 3924
2021
Q1 		– Sell
-4
Closed -$26K – 4289
2020
Q4 		$26K Buy
+4
New +$27.8K ﹤0.01% 4292

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Credit Suisse's AVTX Position: Q3 2022 in Review

Credit Suisse held its Avalo Therapeutics (AVTX) position steady in Q3 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4037.

Credit Suisse first reported a position in AVTX in Q4 2020 and has held it in 1 quarter since. The position peaked at $26K in Q4 2020. 18 funds tracked by Wall St. Rank hold AVTX as of Q3 2022.

  • Credit Suisse held 0 shares of Avalo Therapeutics worth $0 as of Q3 2022.
  • Credit Suisse left its Avalo Therapeutics share count unchanged in Q3 2022.
  • Avalo Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q3 2022, its #4037 holding.
  • Credit Suisse first reported a position in Avalo Therapeutics in Q4 2020 and has held it in 1 quarter since.
  • Credit Suisse's Avalo Therapeutics position peaked at $26K in Q4 2020.
  • 18 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.